A novel gene delivery platform based on a commensal human anellovirus demonstrates transduction in multiple tissue types
简介:
- 作者: Cato Prince, George Bounoutas, Bolu Zhou, Waseem Raja, Isabella Gold, Riana Pozsgai, Parmi Thakker, Nicole Boisvert, Christopher Reardon, Stephanie Thurmond, Erin Ozturk, Rajendra Boggavarapu, Jenna Antonucci Johnson, Patricio Jeraldo, Simeon Springer, Lovepreet Chahal, Emily Stead, Cameron Dodier, Bryan Vought, Maciej Nogalski, Dhananjay Nawandar, Christopher Wright, Ashley Mackey, Geoffrey Parsons, Joseph Cabral
- 杂志: Molecular Therapy
- Doi: https://www.doi.org/10.1016/j.omtm.2025.101597
- 出版日期: 2025/12/11
摘要
Anelloviridae is a family of non-enveloped viruses with negative-sense, circular, single-stranded DNA genomes that infect vertebrates and are a ubiquitous component of the human virome. The non-pathogenic and commensal nature of anelloviruses makes them compelling candidates as vectors for next-generation genetic medicines. Here we report development of a gene delivery vector system based on an anellovirus of the Betatorquevirus genus. Production is enabled by the development of the self-amplifying trans-complementation of a universal recombinant Anellovector (SATURN) system, which relies on a self-replicating plasmid to provide viral proteins in trans and a Cre-lox-based recombination mechanism to generate single unit-sized circular genomes inside the MOLT-4 production cell line. We demonstrate that the SATURN system can package a vector genome from a single Betatorquevirus with capsids from multiple Betatorquevirus species, supporting the feasibility of establishing a vector platform that takes advantage of anellovirus diversity. The vector demonstrated long-term in vivo function in the mouse eye for 12 months post subretinal administration. Comparable gene expression was achieved to dose-matched adeno-associated virus 9 in vitro and in vivo when transducing HEK293TT cells and the murine brain, respectively. To our knowledge, this is the first report of a functional anellovirus-based gene expression vector.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。